Vaccination, Previous Infection Protect Against COVID-19
During period of delta predominance, protection was lower among vaccinated persons without previous COVID-19 diagnosis
During period of delta predominance, protection was lower among vaccinated persons without previous COVID-19 diagnosis
After mRNA-1273 boost, neutralization titers against the omicron variant 20.0 times higher than than those at 1 month after second dose
Findings from an ongoing randomized, placebo-controlled, observer-blind phase 3 trial showed Spikevax was 93.2% effective at preventing COVID-19.
Vaccine, which has been available for the age group under emergency use authorization, will be marketed as Spikevax
However, odds ratios were higher for omicron suggesting that booster doses are less protective than against delta
Compared with homologous booster, heterologous booster with mRNA-based vaccine yielded larger increase in binding antibodies
Supreme Court said mandate went too far in imposing such a sweeping requirement on employers
New US study will assess the updated, omicron-targeted vaccine for use as a booster or for primary vaccinations
But protection against COVID-19 hospitalization, death after 2 doses of BNT162b2 or CHAdOx1-S is more durable
The NCCN Advisory Committee supports the strong preference for mRNA vaccines and offers guidance on the timing of vaccination